相关实验视频
Updated: Jun 25, 2026

04:52
Repetitive Blood Sampling from the Subclavian Vein of Conscious Rat
Published on: February 9, 2022
5.9K
新利配方在心力衰竭中的有效性:通过广东TCM医院数据库进行分析
Haiming Cao1,2, Jiongming Zhang3, Tong Zhang1,2
1Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Frontiers in pharmacology
|December 3, 2025
概括
新利配方显著改善了心力衰竭患者的心脏功能和生活质量. 这种传统中医药可以作为心力衰竭管理的有效辅助疗法.
科学领域:
- 心脏病学 心脏病学
- 综合医学是一个整体的医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是一种复杂的临床综合征,其特点是心脏功能受损.
- 目前的治疗方法旨在改善症状,心脏功能和生活质量,但不断寻求进展.
- 传统中医 (TCM) 配方越来越多地被探索其在各种条件下的治疗潜力,包括高频率.
研究的目的:
- 评估新利配方在改善心脏功能的有效性.
- 评估新利配方对心力衰竭患者症状和生活质量的影响.
- 确定新利配方作为心力衰竭辅助疗法的潜力.
主要方法:
- 一项回顾性研究分析了210名心力衰竭患者 (2017-2022) 的数据.
- 患者被分为新利配方组 (n=107) 和非新利配方组 (n=103).
- 结果包括心脏功能参数 (LVEF,LVESD,LVEDD),NT-proBNP,6MWD,MLHFQ分数和炎症标志物.
主要成果:
- 新利配方组在左心室喷射率 (LVEF) 和左心室末缩直径 (LVESD) 和左心室末缩直径 (LVEDD) 显著改善.
- 在6分钟步行距离 (6MWD) 和生活质量 (明尼苏达生活心力衰竭问卷 - MLHFQ分数) 中观察到显著改善.
- 还注意到N端B型亲尿素 (NT-proBNP) 水平和炎症标志物的降低.
结论:
- 新利配方在增强心脏功能和心力衰竭患者的运动耐受性方面表现出显著的有效性.
- 这种配方显著改善了患有心力衰竭的个体的生活质量.
- 新利配方具有作为治疗心力衰竭的有效辅助疗法的潜力,需要进一步研究.
相关概念视频
Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

